The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant: Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations

Biochemical Pharmacology

Volumn 64, Issue 9, 2002, Pages 1387-1398

  Bapiro, Tashinga E ^a   Hasler, Julia A ^a   Ridderström, Marianne ^b   Masimirembwa, Collen M ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Bufuralol; CYP2D6* 17; Cytochrome P450 2D6; Debrisoquine; Dextromethorphan; Metoprolol

Indexed keywords

BUFURALOL; CLOMIPRAMINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; FLUPHENAZINE; ISOENZYME; METOPROLOL; PROPAFENONE; SPARTEINE; THIORIDAZINE; TIMOLOL;

ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DEMETHYLATION; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYDROXYLATION; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS;

AFRICA; ALLELES; AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CYTOCHROME P-450 CYP2D6; GENETICS, POPULATION; HUMANS; KINETICS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHENOTYPE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0036828964     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01351-5     Document Type: Article

References (68)

1. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
2. Smith D.A., Bel S.M., Hyland R., Jones B.C. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica. 28:1998;1095-1128.
3. Vandel P., Haffen E., Vandel S., Bonin B., Nezelof S., Sechter D., Broly F., Bizouard P., Dalery J. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur. J. Clin. Pharmacol. 55:1999;659-665.
4. Droll K., Bruce-Mensah K., Otton S.V., Gaedigk A., Sellers E.M., Tyndale R.F. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics. 8:1998;325-333.
5. Alvan G., Bechtel P., Iselius L., Gundert-Remy U. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 36:1990;533-537.
6. Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H., Zhou B., Liao C., Zhang L. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46:1989;198-207.
7. Masimirembwa C.M., Hasler J.A. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res. Bull. 44:1997;561-571.
8. Lennard M.S., Iyun A.O., Jackson P.R., Tucker G.T., Woods H.F. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics. 2:1992;89-92.
9. Masimirembwa C.M., Hasler J., Bertilsson L., Johansson I., Ingleman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur. J. Clin. Pharmacol. 51:1996;117-122.
10. Johansson I., Lundqvist E., Bertilsson L., Dahl M., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11825-11829.
11. Zanger U.M., Fischer J., Raimundo S., Stüven T., Evert B.O., Schwab M., Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11:2001;573-585.
12. Johansson I., Oscarson M., Yue Q.-Y., Bertilsson L., Sjöqvist F. Genetic analysis of the Chinese cytochrome P450 2D locus: characterisation of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46:1994;452-459.
13. *10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380:2000;303-308.
14. Lai M.L., Wang S.L., Lai M.D., Lin E.T., Tse M., Huang J.D. Propanolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 58:1995;264-268.
15. Tseng C.Y., Wang S.L., Lai M.D., Lai M.L., Huang J.D. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 60:1996;177-182.
16. Yue Q.Y., Zhong Z.H., Tybring G., Dalén P., Dahl M.L., Bertilsson L., Sjöqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 64:1998;384-390.
17. Wood A.J.J., Zhou H.H. Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet. 20:1991;350-373.
18. *17) common in a black African population: association with diminished hydroxylase activity. Br. J. Clin. Pharmacol. 42:1996;713-719.
19. Wan Y.Y., Poland R.E., Han G., Konishi T., Zheng Y., Berman N., Lin K. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics. 11:2001;489-499.
20. *17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 52:1997;1034-1040.
21. Crespi C.L., Steimel D.T., Penman B.W., Korzekwa K.R., Fernandez-Salguero P., Buters J.T.M., Gelboin H.V., Gonzalez F.J., Idle J.R., Daly A.K. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics. 5:1995;234-243.
22. Pearce R.E., Mcintyre C.J., Madan A., Sanzgiri U., Draper A.J., Bullock P.L., Cook D.C., Burton A.L., Latham J., Nevins C., Parkinson A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 331:1996;145-169.
23. Gietz D., St Jean A., Woods R.A., Schiestl R.H. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20:1992;142-145.
24. Masimirembwa C.M., Otter C., Berg M., Jönsson M., Leidvik B., Jonsson E., Johansson T., Bäckman A., Edlund A., Andersson T.B. Heterologous expression and kinetic characterisation of human cytochrome P450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab. Dispos. 27:1999;1117-1122.
25. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes: evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
26. Markwell M.A.K., Has S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:1978;206-210.
27. Kronbach T., Mathys D., Gut J., Catin T., Meyer U.A. High performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylation in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162:1987;24-32.
28. Chiu F.C., Damani L.A., Li R.C., Tomlinson B. Efficient high-performance liquid chromatographic assay for the simultaneous determination of metoprolol and two main metabolites in human urine by solid-phase extraction and fluorescence detection. J. Chromatogr. B. Biomed. Sci. Appl. 696:1997;69-74.
29. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1994;1469-1479.
30. Crespi C.L. Xenobiotic-metabolising human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26:1995;179-235.
31. Williams P.A., Cosme J., Sridhan V., Johnson E.F., McRee D.E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 5:2000;121-131.
32. Afzelius L., Zamora I., Ridderström M., Andersson T.B., Karlen A., Masimirembwa C.M. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional structure-activity relationship analysis. Mol. Pharmacol. 59:2001;909-919.
33. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:1997;727-748.
34. Venkatakrishnan K., Von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28:2000;1493-1505.
35. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:1992;83-90.
36. de Groot M.J., Vermeulen N.P.E., Kramer J.D., van Acker F.A.A., Donne-Op den Kelder G.M. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, P450 108. Chem. Res. Toxicol. 9:1996;1079-1091.
37. Poli-Scaife S., Attias R., Dansette P.M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry. 36:1997;12672-12682.
38. Schlichting I., Berendzen J., Chu K., Stock A.M., Maves S.A., Benson D.E., Sweet R.M., Ringe D., Petsko G.A., Sligar S.G. The catalytic pathway of cytochrome P450cam at atomic resolution. Science. 287:2000;1615-1622.
39. Marcucci K.A., Pearce R.E., Crespi C., Steimel D.T., Leeder J.S., Gaedisk A. Characterisation of cytochrome P450 2D6.1 (CYP2D6), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos. 30:2002;595-601.
40. Poolsup N., Wan A.L., Knight T.L. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25:2000;197-220.
41. Schadel M., Wu D., Otton V., Kalow W., Sellers E.M. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol. 15:1995;263-269.
42. Jazwinska-Tarnawska E., Orzechowska-Juzwenko K., Niewinski P., Rzemislawska Z., Loboz-Grudzien K., Dmochowska-Perz M., Slawin J. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Int. J. Clin. Pharmacol. Ther. 39:2001;288-292.
43. von Bahr C., Movin G., Nordin C., Lid én A., Hammaarlund-Udenaes M., Hedberg A., Ring H., Sjöqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 49:1991;234-240.
44. Dayer P., kuble A., Küpfer A., Courvoisier F., Balant L., Fabre J. Defective hydroxylation of bufuralol associated with side effects of the drug in poor metabolisers. Br. J. Clin. Pharmacol. 13:1982;750-752.
45. Lennard M.S., Silas J.H., Freestone S., Ramsay L.E., Tucker G.T., Woods H.F. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307:1982;1558-1560.
46. Lewis R.V., Lennard M.S., Jackson P.R., Tucker G.T., Ramsay L.E., Woods H.F. Timolol, atenolol and oxidation phenotype. Br. J. Clin. Pharmacol. 18:1984;287.
47. Nielsen K.K., Brøsen K., Gram L.F. Steady state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur. J. Clin. Pharmacol. 43:1992;405-411.
48. Kilonzo G.P., Kaaya S.F., Rweikiza J.K., Kassam M., Moshi G. Determination of appropriate clomipramine dosage among depressed African outpatients in Dares Salaam, Tanzania. Cent. Afr. J. Med. 40:1994;178-182.
49. Dandara C., Masimirembwa C.M., Magimba A., Sayi J., Kaaya S., Sommers D.K., Snyman J.R., Hasler J.A. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol. 57:2000;11-17.
50. Wennerholm A., Johansson I., Massele A.Y., Lande M., Alm C., Aden-Abdi Y., Dahl M.L., Ingleman-Sundberg M., Bertilsson L., Gustafsson L.L. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics. 9:1999;707-714.
51. Ziegler V.E., Biggs J.T. Tricyclic plasma levels: effect of age, race, sex and smoking. JAMA. 238:1977;2167-2169.
52. *17 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther. 71:2002;77-88.
53. Griese E.-U., Asante-Poku S., Ofori-Adjei D., Mikus G., Eichelbaum M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a west African population. Pharmacogenetics. 9:1999;715-723.
54. *17 alleles to the high prevalence of the intermediate metabolic phenotype. Br. J. Clin. Pharmacol. 47:1999;121-124.
55. Leathart J.B.S., London S.J., Steward A., Adams J.D., Idle J.R., Daly A.K. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 8:1998;529-541.
56. Modi S., Paine M.J., Sutcliffe M.J., Lian L.Y., Primrose W.U., Wolf C.R., Roberts G.C.K. A model for human cytochrome P450 2D6 based on homology modelling and NMR studies of substrate binding. Biochemistry. 35:1996;4540-4550.
57. Lewis D.F.V., Eddershaw P.J., Goldfarb P.S., Tarbit M.H. Molecular modelling of cytochrome P450 2D6 (CYP2D6) based on an alignment with CYP102 structural studies on specific CYP2D6 substrate metabolism. Xenobiotica. 27:1997;319-340.
58. Lewis D.F.V. The CYP2 family: models, mutants and interactions. Xenobiotica. 28:1998;617-661.
59. Ellis S.W., Rowland K., Ackland M.J., Rekka E., Simula A.P., Lennard M.S., Wolf C.R., Tucker G.T. Influence of amino acid residue 374 of cytochrome P450 2D6, CYP2D6, on the regio- and enantio-selective metabolism of metoprolol. Biochem. J. 316:1996;647-654.
60. de Groot M.J., Ackland M.J., Horne V.A., Alex A.A., Jones B.C. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42:1999;1515-1524.
61. Koymans L., Vermeulen N.P.E., van Acker S.A.B.E., te Koppele J.M., Heykants J.J.P., Lavrijsen K., Meuldermans W., den Kelder G.M.D. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5:1992;211-219.
62. Poulos T.L. Modeling of mammalian P450s on basis of P450cam X-ray structure. Methods Enzymol. 206:1991;11-30.
63. Lightfoot T., Ellis S.W., Mahling J., Ackland M.J., Blaney F.E., Bijloo G.J., De Groot M.J., Vermeulen N.P., Blackburn G.M., Lennard M.S., Tucker G.T. Regioselective hydroxylation of debrisoquine by cytochrome P450 2D6: implication for active site modelling. Xenobiotica. 30:2000;219-233.
64. Otton S.V., Crewe H.K., Lennard M.S., Tucker G.T., Woods H.F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247:1988;242-247.
65. Yamazaki H., Guo Z., Peersmark M., Mimura M., Inoue K., Peter G., Shimada T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46:1994;568-577.
66. Von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Schmider J., Harmatz J.S., Shader R.I. Multiple human cytochormes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6 and CYP3A. J. Pharm. Pharmacol. 50:1998;997-1004.
67. Ebner T., Meese C.O., Eichelbaum M. Mechanism of cytochrome P450 2D6-catalysed sparteine metabolism in humans. Mol. Pharmacol. 48:1995;1078-1086.
68. Olesen O.V., Linnet K. Identification of the human cytochrome P450 isoforms mediating the in vitro N-dealkylation of perphenazine. Br. J. Clin. Pharmacol. 50:2000;563-571.